For the quarter ending 2026-03-31, CGTX had -$5,775K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Grant income | 3,979 | 9,999 | 13,407 | - |
| Clinical programs | 3,381 | 8,647 | 16,486 | - |
| R&d personnel costs | 1,594 | 1,522 | 6,221 | - |
| Preclinical programs | 619 | 184 | 262 | - |
| Manufacturing | 337 | 642 | 1,901 | - |
| Other research and development expenses | 51 | 8 | 222 | - |
| General and administrative expenses (excluding equity-based compensation) | - | 2,310 | 2,387 | - |
| General and administrative expenses | 2,505 | - | - | - |
| Equity-based compensation | 330 | 358 | 1,729 | - |
| Other segment items | -268 | -329 | -577 | - |
| Net loss | -4,570 | -3,343 | -4,930 | -15,214 |
| Depreciation and amortization | 11 | 14 | 15 | 7 |
| Equity-based compensation | 330 | 358 | 522 | 1,207 |
| Amortization of right-of-use assets | 57 | 47 | 46 | 99 |
| Realized loss on disposal of property and equipment | -5 | -41 | - | - |
| Grant receivables | -6,266 | 8,023 | -4,385 | 3,599 |
| Prepaid expenses and other assets | -136 | -473 | -47 | -653 |
| Accounts payable and accrued expenses | -7,570 | 8,414 | -5,443 | 539 |
| Deferred grant income and other liabilities | -147 | -1,369 | -246 | 916 |
| Operating lease liabilities | -60 | -49 | -47 | -108 |
| Net cash used in operating activities | -5,542 | -3,437 | -5,651 | -15,500 |
| Proceeds from sale of property and equipment | - | 9 | - | - |
| Net cash used in investing activities | - | 9 | - | - |
| Proceeds from issuance of common stock-Registered Direct Offering | - | -50 | 27,940 | - |
| Proceeds from issuance of common stock-At Market Offering | - | 800 | 5,989 | 2,337 |
| Proceeds from the exercise of common stock options | 44 | 6 | 65 | - |
| Payment of employee withholding taxes on vested restricted stock units | 164 | 77 | 36 | 51 |
| Payments on loan payable | 113 | 74 | 41 | 238 |
| Net cash provided (used) by financing activities | -233 | 605 | 33,917 | 2,048 |
| Net decrease in cash, cash equivalents and restricted cash equivalents | -5,775 | -2,823 | 28,266 | -13,452 |
| Cash, cash equivalents, and restricted cash equivalents - beginning of period | 37,000 | 39,823 | 25,009 | - |
| Cash, cash equivalents, and restricted cash equivalents - end of period | 31,225 | 37,000 | 39,823 | - |
COGNITION THERAPEUTICS INC (CGTX)
COGNITION THERAPEUTICS INC (CGTX)